Zacks Investment Research upgraded shares of Selecta Biosciences (NASDAQ:SELB) from a sell rating to a hold rating in a report issued on Wednesday.
According to Zacks, “Selecta Biosciences, Inc. is a biopharmaceutical company which develops targeted immunotherapies and vaccines. Its product pipelineincludes gene therapy, food allergy, malaria; SEL-212, which is a therapeutic enzyme indicated for refractory gout; SEL-070, which is indicated for smoking cessation and relapse prevention; SEL-701, which is indicated for the treatment of human papillomavirus associated cancer and SEL-212 consists of SVP-Rapamycin co-administered with pegsiticase, its pegylated uricase. Selecta Biosciences, Inc. is based in Watertown, United States. “
Several other brokerages also recently weighed in on SELB. Mizuho restated a buy rating and set a $30.00 price target on shares of Selecta Biosciences in a report on Thursday, August 9th. ValuEngine raised Selecta Biosciences from a sell rating to a hold rating in a research report on Thursday, July 5th. Canaccord Genuity reaffirmed a buy rating and set a $40.00 price objective on shares of Selecta Biosciences in a research report on Thursday, June 28th. BidaskClub cut Selecta Biosciences from a buy rating to a hold rating in a research report on Friday, October 5th. Finally, Janney Montgomery Scott started coverage on Selecta Biosciences in a research report on Wednesday, June 27th. They set a buy rating and a $33.00 price objective for the company. Four investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The company presently has a consensus rating of Buy and an average price target of $27.40.
NASDAQ SELB traded up $1.05 during trading hours on Wednesday, hitting $14.23. 196,196 shares of the company were exchanged, compared to its average volume of 217,394. The company has a debt-to-equity ratio of 0.87, a current ratio of 4.96 and a quick ratio of 4.96. Selecta Biosciences has a 52-week low of $7.95 and a 52-week high of $24.02. The company has a market cap of $348.26 million, a price-to-earnings ratio of -4.45 and a beta of -3.47.
Selecta Biosciences (NASDAQ:SELB) last issued its quarterly earnings results on Wednesday, August 8th. The company reported ($0.84) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.68) by ($0.16). Equities research analysts anticipate that Selecta Biosciences will post -3.07 earnings per share for the current fiscal year.
Large investors have recently added to or reduced their stakes in the company. Rhumbline Advisers boosted its position in shares of Selecta Biosciences by 43.7% during the 2nd quarter. Rhumbline Advisers now owns 16,792 shares of the company’s stock worth $222,000 after acquiring an additional 5,103 shares in the last quarter. Proxima Capital Management LLC acquired a new position in shares of Selecta Biosciences during the 2nd quarter worth about $1,075,000. BlackRock Inc. boosted its position in shares of Selecta Biosciences by 1.6% during the 1st quarter. BlackRock Inc. now owns 629,978 shares of the company’s stock worth $6,420,000 after acquiring an additional 9,749 shares in the last quarter. Wasatch Advisors Inc. boosted its position in shares of Selecta Biosciences by 9.2% during the 2nd quarter. Wasatch Advisors Inc. now owns 235,625 shares of the company’s stock worth $3,122,000 after acquiring an additional 19,803 shares in the last quarter. Finally, A.R.T. Advisors LLC boosted its position in shares of Selecta Biosciences by 225.5% during the 1st quarter. A.R.T. Advisors LLC now owns 59,584 shares of the company’s stock worth $607,000 after acquiring an additional 41,277 shares in the last quarter. 48.74% of the stock is owned by institutional investors and hedge funds.
About Selecta Biosciences
Selecta Biosciences, Inc, a clinical-stage biopharmaceutical company, researches and develops nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. Its proprietary pipeline includes synthetic vaccine particles (SPV)-enabled enzyme, oncology, and gene therapies. The company's lead product is SEL-212 that in Phase II clinical trial to treat severe gout patients and resolve their symptoms, including flares and gouty arthritis.
Further Reading: Cash Flow Analysis in Stock Selection
Get a free copy of the Zacks research report on Selecta Biosciences (SELB)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Selecta Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Selecta Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.